Salzgitter Aktiengesellschaft

  • WKN: 620200
  • ISIN: DE0006202005
  • Land: Deutschland

Nachricht vom 07.09.2021 | 11:08

Salzgitter Aktiengesellschaft: Expectations for the best pre-tax result in a decade: Salzgitter Group raises its profit guidance again for the financial year 2021

Salzgitter Aktiengesellschaft / Key word(s): Change in Forecast
Salzgitter Aktiengesellschaft: Expectations for the best pre-tax result in a decade: Salzgitter Group raises its profit guidance again for the financial year 2021

07-Sep-2021 / 11:08 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Following the strong first half year, the Salzgitter Group's good performance continued in the summer quarter as well. The sustained upbeat development in prices and demand is especially reflected in the excellent results of the Strip Steel and Trading business units. Furthermore, the margin situation in the section steel product segment improved, enabling the Plate / Section Steel Business Unit to achieve better results than formerly anticipated. Consequently, and provided that the market continues its stable development through to the end of the year despite the latent coronavirus crisis, we are raising our profit guidance again for the financial year 2021 and now assume a pre-tax profit of between € 600 million and € 700 million for the Salzgitter Group (previously: between € 400 million and € 600 million).

 

Contact:
Markus Heidler

Head of Investor Relations

Salzgitter AG
Eisenhüttenstraße 99
38239 Salzgitter

Phone +49 5341 21-6105
Fax +49 5341 21-2570
E-Mail ir@salzgitter-ag.de

07-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021